INTERNATIONAL JOURNAL OF MEDICAL SCIENCE AND DENTAL HEALTH

Volume03 Issue04, Apr-2017, pg. 01-04

Published Date: - 02-04-2017

E-ISSN: 2454-4191
P-ISSN: 2455-0779

ORAL SUBMUCOUS FIBROSIS: UNRAVELING AETIOLOGY AND ADVANCING MANAGEMENT CONCEPTS

Pushup raj Mishra

Assistant Professor, Department of Oral Medicine and Radiology, Rishiraj College of Dental Sciences, Bhopal, India

Abstract: Oral submucous fibrosis (OSF) is a potentially debilitating, chronic, and progressive oral mucosal disorder that predominantly affects individuals in Southeast Asia and other parts of the world. The exact etiology of OSF remains multifactorial, involving a combination of genetic predisposition, environmental factors, and the habitual use of areca nut and betel quid. This comprehensive review aims to elucidate the current understanding of OSF's etiological factors and explore the latest advancements in its management. The pathogenesis, clinical features, and histopathological changes associated with OSF are discussed, providing insights into its complex and multifaceted nature. Additionally, the review presents an updated overview of various therapeutic approaches, including medical interventions, surgical treatments, and the potential role of emerging therapies. By shedding light on the intricate aspects of OSF, this review seeks to guide dental and medical professionals in the early diagnosis, prevention, and effective management of this challenging oral condition.

Keywords: Oral submucous fibrosis, etiology, aetiology, areca nut, betel quid, pathogenesis, clinical features, histopathology, management, medical interventions, surgical treatments, emerging therapies, prevention.

INTRODUCTION

Oral submucous fibrosis (OSF) is a potentially debilitating and chronic oral mucosal disorder that has become a major public health concern, particularly in Southeast Asia and other regions with high consumption of areca nut and betel quid. OSF is characterized by progressive fibrosis of the oral mucosa, leading to restricted mouth opening, difficulty in speech and eating, and an increased risk of oral malignancies. The pathogenesis of OSF is complex and multifactorial, involving a combination of genetic predisposition, environmental factors, and the habitual use of areca nut and betel quid. Despite the growing prevalence and severity of OSF, its precise etiology remains incompletely understood.

This review aims to unravel the current concepts of OSF's etiology and provide insights into advancing management strategies. By examining the latest research and clinical evidence, we seek to shed light on the intricate interactions between genetic factors, environmental exposures, and the pathophysiological mechanisms that underlie the development and progression of OSF. Additionally, this review will explore the various therapeutic approaches available for managing OSF, including medical interventions, surgical

Published Date: - 02-04-2017

E-ISSN: 2454-4191
P-ISSN: 2455-0779

treatments, and emerging therapies, in the pursuit of improved patient outcomes and better quality of life for those affected by this condition.

METHOD

A comprehensive literature search was conducted to identify relevant articles, research papers, and clinical studies related to the etiology and management of oral submucous fibrosis. Databases including PubMed, Google Scholar, Scopus, and other medical literature sources were systematically reviewed using relevant keywords such as "oral submucous fibrosis," "etiology," "pathogenesis," "areca nut," "betel quid," "management," "medical interventions," "surgical treatments," and "emerging therapies."

Articles and studies published in English, with a focus on human subjects and experimental models, were included. The search covered a time frame from the earliest available publications to the most recent updates as of the search date. The retrieved literature was critically analyzed, and relevant information was extracted and organized to provide a comprehensive overview of the current understanding of OSF's etiology and management concepts.

The review encompasses a detailed discussion of the identified etiological factors, including the influence of genetic susceptibility, environmental factors, and the complex role of areca nut and betel quid in OSF pathogenesis. Furthermore, the management section explores the various treatment modalities, both conventional and emerging, with a focus on their efficacy and limitations.

By collating and synthesizing the available evidence, this review aims to contribute to the existing knowledge base and offer valuable insights for clinicians, researchers, and policymakers involved in the diagnosis and management of oral submucous fibrosis.

RESULT

The literature review revealed that oral submucous fibrosis (OSF) is a complex and multifactorial oral mucosal disorder, primarily prevalent in Southeast Asia and other regions with a high consumption of areca nut and betel quid. The etiology of OSF involves a combination of genetic predisposition, environmental factors, and the habitual use of areca nut and betel quid. The pathogenesis of OSF is characterized by fibrosis of the oral mucosa, leading to progressive restriction of mouth opening and potential malignant transformation. Various therapeutic approaches, including medical interventions, surgical treatments, and emerging therapies, have been explored to manage OSF and improve patient outcomes.

DISCUSSION

The etiology of OSF is multifaceted, with genetic factors and environmental exposures playing critical roles in its development. Genetic predisposition, identified through familial aggregation studies, highlights the

Published Date: - 02-04-2017

E-ISSN: 2454-4191
P-ISSN: 2455-0779

contribution of genetic variations in collagen and matrix metalloproteinase genes to the disease's susceptibility. However, the exact genetic mechanisms remain to be fully elucidated.

Environmental factors, particularly the habitual use of areca nut and betel quid, have been recognized as significant contributors to OSF's pathogenesis. Areca nut contains arecoline, an alkaloid that induces fibrosis by promoting collagen synthesis and inhibiting collagen degradation. Additionally, betel quid constituents, such as catechin and tannins, exhibit pro-fibrotic properties, exacerbating OSF progression. Furthermore, the synergistic effect of tobacco and other irritants in betel quid enhances the risk of malignant transformation in OSF patients.

Management of OSF involves a multidimensional approach, considering the severity of the disease and the patient's overall health status. Medical interventions, such as antioxidants, immunomodulators, and collagenase inhibitors, have shown promise in halting or reversing fibrosis in early-stage OSF. However, the results may vary among individuals, and more extensive clinical trials are needed to establish their long-term efficacy.

Surgical treatments, such as intralesional injections of corticosteroids and hyaluronidase, have demonstrated benefits in improving mouth opening and relieving symptoms. However, the risk of complications and recurrence requires careful consideration. Surgical excision of fibrotic bands can provide functional improvements, but recurrence and the potential for postoperative scarring necessitate cautious patient selection.

Emerging therapies, including the use of pentoxifylline, curcumin, and other novel agents, show promise in targeting specific molecular pathways involved in OSF pathogenesis. These therapies hold potential for more targeted and effective management, but further research is essential to establish their safety and efficacy in larger patient populations.

CONCLUSION

Oral submucous fibrosis is a challenging oral mucosal disorder with a complex etiology involving genetic predisposition and environmental factors, particularly the habitual use of areca nut and betel quid. The advancement in understanding OSF's pathogenesis has led to the development of various management concepts, including medical interventions, surgical treatments, and emerging therapies. However, the optimal management approach remains elusive, and more extensive research is warranted to identify targeted therapies and improve long-term treatment outcomes.

Enhanced awareness and early diagnosis are crucial to prevent disease progression and potential malignant transformation. Dental and medical professionals must collaborate to address this public health concern and develop comprehensive strategies for OSF prevention and management. By unraveling the aetiology and advancing management concepts, this review aims to provide valuable insights to guide future research and clinical practice in tackling this challenging oral condition effectively.

Published Date: - 02-04-2017

E-ISSN: 2454-4191
P-ISSN: 2455-0779

REFERENCES

1. Taneja L, Bagewadi A, Keluskar V.Haemoglobin levels in patients with oral submucous fibrosis. Journal of Indian Academy of Oral Medicine and Radiology 2007; 19 (2): 329-333.
2. Sodhi S, Sodhi JS, Khambete N, Kumar R, Marthala M, Sodhi NK. Expression of tumor necrosis factor alpha and its correlation with severity of oral submucous fibrosis: a case- control study. Oral Surg Oral Med Oral Pathol Oral Radiol 2014; 117: 704- 708.
3. Pindborg JJ. Oral Submucous Fibrosis as a Precancerous Condition. Journal Dental Research 1966; 45(3): 546-553.
4. Rajalalitha P & Valli S. Molecular pathogenesis of oral submucous fibrosis- a collagen metabolic disorder. J Oral Pathol Med 2005; 34: 321-8
5. Dyavanagoudar SN. Oral Submucous Fibrosis: Review on Etiopathogenesis. J Canc Sci Ther 2009; 1(2): 072-077.
6. Rajendran R. Oral Submucous Fibrosis. Journal of Oral and Maxillofacial Pathology Jan- Jun 2003; 7 (1): 1- 4.
7. Mehta FS and Hammer JE. Tobacco- related oral mucosal lesions and conditions in India. 1993 Basic Dental Research Unit, Tata Institute of Fundamental Research Bombay. Jaypee Brothers Medical Publishers (P) Ltd. page 56-67.
8. Satheeshkumar PS, Mohan MP, Jacob J. Restricted mouth opening and trismus in oral oncology. Oral Surg Oral Med Oral Pathol Oral Radiol 2014; 117: 709-715.
9. Haider SM, Merchant AT, Fikree FF, Rahbar MH.. Clinical and functional staging of oral submucous fibrosis. British Journal of Oral and Maxillofacial Surgery; 2000; 38: 12–15.